BD (Becton, Dickinson and Company) has made a significant stride in the medical technology landscape by securing CE Marking for its Revello Vascular Covered Stent. This cutting-edge endovascular solution targets atherosclerotic lesions within the common and external iliac arteries, addressing a critical health concern related to lower-extremity peripheral artery disease (PAD). With its potential to alleviate the disability burden faced by an aging population across the European Union, the Revello Stent represents a timely advancement in patient care.
A Game-Changer in Peripheral Vascular Health
The Revello Vascular Covered Stent is engineered to enhance iliac artery revascularization. Rima Alameddine, BD’s worldwide president of Interventional – Peripheral Intervention, emphasized the importance of this innovation, stating it aims to elevate treatment standards while expanding BD’s peripheral vascular portfolio. The device’s design incorporates the flexibility of a nitinol self-expanding stent, coupled with a radial resistive force specifically tailored for iliac arteries.
Design Features for Optimal Performance
This self-expanding stent features an ultrathin expanded polytetrafluoroethylene covering that helps maintain the patency of iliac arteries while adapting to the unique anatomy of each vessel. The compliant stent ends are specifically crafted to minimize trauma to healthy vessel segments, thus promoting safer procedures. Tantalum radiopaque markers are integrated within the stent to facilitate clear visualization during fluoroscopy, even in complex anatomical scenarios.
Precision Delivery System
The Revello Stent is deployed using an innovative tri-axial delivery system, which enhances both control and accuracy during placement. This system includes an atraumatic tip for easy insertion, a stability sheath for precise delivery, and a thumbwheel mechanism that allows for intuitive adjustments throughout the deployment process. With a broader range of diameters on a lower-profile platform than existing self-expanding iliac artery stents in Europe, the Revello Stent reduces the likelihood of access site complications.
Clinical Trials and Future Prospects
BD introduced the Revello Stent at the LINC 2026 congress in Germany, where physicians explored its implications for iliac interventions. Dr. Michael Lichtenberg, a physician and angiologist, highlighted the ongoing AGILITY clinical trial that is assessing the device’s performance in patients suffering from PAD. This multi-center study, led by Dr. Sean Lyden of the Cleveland Clinic and Dr. Lichtenberg himself, aims to provide valuable insights into the stent’s clinical effectiveness.
A Promising Treatment Option
Dr. Lichtenberg remarked on the advantages of the Revello Stent, noting its high radial force and low profile. The device’s tri-axial delivery system allows for easy and precise placement, making it a compelling option for clinicians dealing with iliac artery conditions. The positive feedback from physicians underscores the potential of this innovative stent to significantly improve treatment outcomes.
Launch and Market Availability
With the CE Mark grant, BD is set to launch the Revello Stent across CE-mark-accepting countries in Europe. However, in the United States, it remains an investigational device limited to research use only. This distinction highlights the ongoing commitment to ensuring the stent meets the rigorous standards required for widespread clinical application.
Looking Ahead
BD’s Revello Vascular Covered Stent embodies a vital advancement in the treatment of iliac artery disease. As the EU grapples with the increasing prevalence of PAD, this innovative solution paves the way for improved patient outcomes. The ongoing clinical trials will provide further insights, potentially solidifying the Revello Stent’s place in therapeutic protocols.
Takeaways:
- The Revello Vascular Covered Stent received CE Marking, marking a significant advancement in PAD treatment.
- Its design prioritizes flexibility and safety, featuring an ultrathin covering and compliant stent ends.
-
A tri-axial delivery system enhances placement accuracy and reduces complications.
-
Ongoing clinical trials will assess the stent’s effectiveness in treating patients with PAD.
In conclusion, BD’s Revello Stent is poised to transform the landscape of iliac artery treatments, offering hope to many patients affected by peripheral artery disease. Its innovative design and clinical potential promise to raise the standard of care in vascular interventions across Europe.
Read more → www.finanznachrichten.de